Ken Griffin 10x Genomics, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in 10x Genomics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 26,200 shares of TXG stock, worth $423,654. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,200

Previous 108,300 75.81%

Holding current value

$423,654

Previous $4.06 Million 87.48%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$19.45 - $37.37 $4.81 Million - $9.24 Million	247,234 Added 283.66%	334,393 $6.5 Million
Q1 2024 May 15, 2024	SELL	$36.08 - $54.3 $976,541 - $1.47 Million	-27,066 Reduced 23.7%	87,159 $3.27 Million
Q4 2023 Feb 14, 2024	BUY	$34.32 - $57.55 $3.39 Million - $5.69 Million	98,920 Added 646.32%	114,225 $6.39 Million
Q3 2023 Nov 14, 2023	SELL	$40.86 - $62.98 $28.9 Million - $44.5 Million	-706,265 Reduced 97.88%	15,305 $631,000
Q2 2023 Aug 14, 2023	SELL	$50.96 - $58.72 $25.9 Million - $29.9 Million	-508,557 Reduced 41.34%	721,570 $40.3 Million
Q1 2023 May 15, 2023	SELL	$35.33 - $55.79 $8.26 Million - $13 Million	-233,774 Reduced 15.97%	1,230,127 $68.6 Million
Q4 2022 Feb 14, 2023	BUY	$24.4 - $41.3 $27.1 Million - $45.8 Million	1,108,820 Added 312.27%	1,463,901 $53.3 Million
Q3 2022 Nov 14, 2022	BUY	$28.48 - $52.59 $6.33 Million - $11.7 Million	222,348 Added 167.52%	355,081 $10.1 Million
Q2 2022 Aug 15, 2022	BUY	$36.95 - $82.41 $4.7 Million - $10.5 Million	127,117 Added 2263.48%	132,733 $6.01 Million
Q4 2021 Feb 14, 2022	SELL	$135.05 - $182.59 $8.04 Million - $10.9 Million	-59,506 Reduced 91.38%	5,616 $836,000
Q3 2021 Nov 15, 2021	SELL	$145.58 - $192.14 $1.47 Million - $1.94 Million	-10,108 Reduced 13.44%	65,122 $9.48 Million
Q2 2021 Aug 16, 2021	BUY	$134.22 - $202.37 $9.74 Million - $14.7 Million	72,604 Added 2764.81%	75,230 $14.7 Million
Q1 2021 May 17, 2021	SELL	$140.25 - $196.86 $28.5 Million - $40 Million	-203,255 Reduced 98.72%	2,626 $475,000
Q4 2020 Feb 16, 2021	BUY	$126.47 - $163.7 $11.3 Million - $14.6 Million	89,316 Added 76.62%	205,881 $29.2 Million
Q3 2020 Nov 16, 2020	BUY	$87.44 - $125.0 $9.97 Million - $14.3 Million	114,008 Added 4458.66%	116,565 $14.5 Million
Q2 2020 Aug 14, 2020	SELL	$58.39 - $89.31 $1.49 Million - $2.28 Million	-25,504 Reduced 90.89%	2,557 $228,000
Q1 2020 May 15, 2020	BUY	$51.57 - $106.62 $229,125 - $473,712	4,443 Added 18.81%	28,061 $1.75 Million
Q4 2019 Feb 14, 2020	SELL	$46.07 - $79.54 $3.77 Million - $6.51 Million	-81,852 Reduced 77.61%	23,618 $1.8 Million
Q3 2019 Nov 14, 2019	BUY	$49.99 - $62.0 $5.27 Million - $6.54 Million	105,470 New	105,470 $5.32 Million

Others Institutions Holding TXG

# of Institutions

287

Shares Held

94.9M

Call Options Held

162K

Put Options Held

107K

View Full List

About 10x Genomics, Inc.

Ticker TXG
Exchange NASDAQ
Sector Healthcare
Industry Health Information Services
Shares Outstandng 95,046,400
Market Cap $1.54B
Description
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumabl...

More about TXG

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account